Olio Labs GTM brain

Olio Labs develops AI-designed combination therapies and preclinical validation tools for drug discovery, including its own obesity programs and research partners.

category

AI combination therapeutics and preclinical discovery

market profile

  • text: Finding effective drug combinations requires navigating interactions among many biological targets and large candidate spaces.
  • text: The company reports an in vivo platform used by partners and its own pipeline; the independent clinical translation of its predictions is not established here.
  • text: An independent research profile found no named clinical-stage assets or trial identifiers in its reviewed sources.

personas

  • title: Pharma discovery and translational research leader
    pains:
    • Computational predictions produce more candidates than conventional in vivo studies can test
    • Animal models do not always predict human efficacy and adverse events
  • title: Metabolic disease portfolio lead
    pains:
    • Needs differentiated obesity candidates that balance benefit and tolerability
    • Combination programs require evidence for each intervention and its interaction
  • title: Biopharma business development director
    pains:
    • Must evaluate quality of preclinical data before committing scarce capital
    • Needs clear rights and responsibilities for collaborative development

icp

  • text: Mid-size and large pharmaceutical companies exploring combination therapies or evaluating preclinical candidates; YC launch explicitly seeks pharma connections.
  • text: Biotech research teams with metabolic disease programs or a high volume of candidates needing in vivo screening; account size is unverified.

message pillars

  • text: Use human data and whole-body models to rank therapies.
  • text: Test top candidates using a high-throughput in vivo platform.
  • text: Pursue better treatment outcomes with fewer side effects.

objections

  • objection: Are better obesity outcomes proven in patients?
    response: Request study designs and clinical evidence; the public profile does not establish clinical-stage assets and preclinical predictions are not patient outcomes.
  • objection: Will the model generalize to our drug and indication?
    response: Review retrospective validation and agree a blinded prospective test against relevant endpoints.
  • objection: Who owns discoveries and how is collaboration priced?
    response: Discuss data access, IP, milestones and cost with the company; public terms were not found.

competitors

  • name: Insilico Medicine
    why: AI drug discovery and internally developed therapeutic programs compete for partnerships and research capital.
  • name: Isomorphic Labs
    why: AI-driven therapeutic discovery platform pursuing pharmaceutical partnerships, though its methods differ.
  • name: Novo Nordisk
    why: Existing obesity medicines compete with a possible future Olio metabolic treatment rather than its discovery service.

influencers

  • name: Tom Roseberry
    url: https://www.ycombinator.com/founders/tom-roseberry
    why: Co-founder working across computational biology and drug development.

keywords

  • AI combination drug discovery
  • obesity combination therapeutics
  • in vivo phenotyping platform
  • preclinical efficacy prediction
  • GLP-1 combination therapy
  • drug side effect prediction

voice

  • Scientifically ambitious
  • Outcome focused
  • Accessible language for complex biology

signals

  • text: A pharma team is expanding metabolic discovery or looking for differentiated combination candidates.
  • text: A discovery group has more computational candidates than its animal testing throughput can accommodate.

hiring

  • Senior Technician, reported on LinkedIn
  • Part-Time In-Vivo Research Technician, reported on LinkedIn

pricing

model: unknown

motion

unknown

channels

  • LinkedIn
  • research and publications
  • pharma partnerships

confidence

medium

Founders

  • name: David Tingley
    title: Founder
    role: Founder
    bio: David has over 13 years of experience as a systems neuroscientist and biologist. His interest in systems biology led him to earn a PhD in Neuroscience at New York University and complete postdoctoral research at Harvard. During this time, he published more than 15 scientific articles and uncovered a link between oscillations in brain activity and glucose metabolism in the body (Tingley et al., Nature 2020).
  • name: Tom Roseberry
    title: Founder
    role: Founder
    bio: Tom has over 15 years of industry experience leading teams and engineering technologies in aerospace, brain machine interfacing, synthetic biology and drug discovery/development. At Neuralink he built and co-led a group that developed a next-generation neural interface. At Loyal he built and led multiple teams as VP of Engineering, Computational Biology and Drug Development.

Back to YC companies